Skip to main content

Month: May 2020

Results of refinancing

To Nasdaq Copenhagen      and the press14 May 2020  Results of refinancingThe Nykredit Group has conducted the bond sales in connection with the refinancing of ARMs based on the “refinancing price” principle. The interest rates will be reset on 1 July 2020.For a personal borrower with a 30Y annuity loan, interest rate reset results in the following cash rates:For detailed information on the auction results, please refer to nykredit.dk and totalkredit.dk. For information on the bond sales, please refer to nykredit.com/ir.Enquiries may be addressed to Anders Madsen, Funding & Capital, tel +45 44 55 11 65 or Corporate Communications, tel +45 44 55 14 50.AttachmentResults of refinancing – Nykredit Realkredit – Totalkredit – 14052020

Continue reading

Resultat af rentetilpasning

Til    Nasdaq Copenhagen       og pressen                                                                             14. maj 2020Resultat af rentetilpasningNykredit koncernen har afsluttet obligationssalget i forbindelse med rentetilpasning af Tilpasningslån efter princippet om ”refinansieringskurs”. Lånene rentetilpasses den 1. juli 2020.Lånene er finansieret med særligt dækkede obligationer (SDO) udstedt i kapitalcenter H.For en privat låntager med et 30-årigt annuitetslån resulterer rentetilpasningen i følgende kontantlånsrenter:Detaljerede oplysninger om auktionsresultaterne kan ses på nykredit.dk og totalkredit.dk. Oplysninger om obligationssalget kan ses på nykredit.com/ir.Spørgsmål kan rettes til Anders Madsen, Funding og Kapital, på telefon 44 55 11 65 eller Kommunikation på telefon 44 55 14 50.Vedhæftet filResultat af rentetilpasning...

Continue reading

Dynacor Reports a Net Income of US$ 2.4 M (US$ 0.06 per Share) or (CAD 0.08 per Share) in Q1-2020, Despite Late Quarter Operation Shutdown

MONTREAL, May 14, 2020 (GLOBE NEWSWIRE) — Dynacor Gold Mines Inc. (TSX: DNG / OTC: DNGDF) (Dynacor or the Corporation) has released its unaudited consolidated financial statements and the management’s discussion and analysis (MD&A) for the first quarter ended March 31, 2020.These documents have been filed electronically with SEDAR at www.sedar.com and will be available on the Corporation’s website www.dynacor.com.(All figures in this press release are in Ms of US$ unless stated otherwise. Earnings per share and cash-flow per share are in US$. All variance % are calculated from rounded figures. Some additions might be incorrect due to rounding).In Q1-2020 Dynacor completed its thirty sixth (36th) consecutive quarter of profits with a net income of $2.4 M (US $0.06 per share) compared to $1.2 M (US $0.03 per share)...

Continue reading

Dynacor annonce un résultat net de 2,4 M$ US (0,06 $ US par action) ou (0,08 $ CA par action) en T1-2020, malgré l’arrêt des opérations en fin de trimestre

MONTRÉAL, 14 mai 2020 (GLOBE NEWSWIRE) — Mines d’or Dynacor Inc. (TSX: DNG) (OTC: DNGDF) (Dynacor ou la Société), une compagnie qui exerce des activités de traitement de minerai d’or et d’argent et détient des projets d’exploration minière au Pérou, vient de déposer ses états financiers consolidés intermédiaires non audités et son rapport de gestion pour la période de trois mois close le 31 mars 2020.Ces documents ont été déposés électroniquement sur SEDAR au www.sedar.com et sont accessibles sur le site Web de la Société au www.dynacor.com. (Tous les montants dans ce communiqué sont en million de dollars américains, à moins d’indication contraire. Le résultat par action et les flux monétaires par action sont en dollars américains. Les montants de % de variation ont été calculés à partir des chiffres arrondis.)Au cours de la période...

Continue reading

Zealand Pharma files New Drug Application with U.S. FDA for dasiglucagon HypoPal® rescue pen, secures DKK 137 million in additional investment, and accelerates readiness of U.S. commercial operations: Interim report for Q1 2020

Zealand Pharma files New Drug Application with U.S. FDA for dasiglucagon HypoPal® rescue pen, secures DKK 137 million in additional investment, and accelerates readiness of U.S. commercial operationsInterim report for Q1 2020Zealand Pharma A/S (Nasdaq: ZEAL) (CVR No. 20045078), a biotechnology company changing lives with innovative peptide-based medicines, today announced financial results for the first quarter of 2020.Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma, comments:“Zealand Pharma continues to deliver on our commitments, as demonstrated by the achievements made in the first quarter of 2020. We submitted the New Drug Application to the U.S. FDA for the dasiglucagon HypoPal® rescue pen on schedule and reported positive topline results from a Phase 2 trial evaluating dasiglucagon in treating post...

Continue reading

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update

LA JOLLA, Calif., May 14, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease today reported its financial results for the first quarter ended March 31, 2020 and is providing a business update. INmune Bio will hold a conference call today at 4:30 PM Eastern Time. To participate in the call, please dial 201-389-0923 five minutes before the schedule time.The company will review the progress on its clinical programs in areas including Alzheimer’s disease and its recently announced effort in combating complications of COVID-19.  The company will also provide guidance for development efforts over the next two quarters based on the ongoing pandemic.“Since our last earning report, we have been working to put...

Continue reading

China Recycling Energy Corporation Reports Results for the Full Year 2019

XI’AN, China, May 14, 2020 (GLOBE NEWSWIRE) — China Recycling Energy Corporation (NASDAQ: CREG) (“CREG” or “the Company”), an industrial waste-to-energy solution provider in China, today reported certain highlights of its audited operating results for the full year ended December 31, 2019.“As of December 31, 2019, we maintained a healthy cash and cash equivalents balance of approximately $16.22 million,” stated Mr. Guohua Ku, Chairman and CEO of the Company. In addition, we have accomplished significant cost cutting throughout our entire organization, evidenced by net loss narrowed by approximately 86.7% to approximately $(8.77) million in fiscal 2019, as compared to approximately $(76.22) million in the same period of fiscal 2018. We are executing what we believe is a clear plan to manage our business...

Continue reading

Wine.com releases Fiscal 2020 and April results

SAN FRANCISCO, May 14, 2020 (GLOBE NEWSWIRE) — Wine.com, the nation’s leading online wine retailer, topped $165 million in revenue and 25% growth for fiscal 2020, ending March 31. The $33 million revenue increase over fiscal 2019 represents the largest year-over-year gain in the company’s history.While these results reflect 2 weeks of shelter-in-place mandates, the full impact was not seen until April, when revenues for the month exceeded $40 million, a 350% increase over April 2019.  This brought trailing 12-month revenue to $197 million – a 47% increase over the comparable prior year period.“Our priority has been to delight these new customers while staying safe,” said Rich Bergsund, Wine.com CEO. “We’ve hired over 500 people onto our operations, customer service and live chat recommendations teams, while moving to same-day shipping,...

Continue reading

Where Food Comes From, Inc. Reports 2020 First Quarter Financial Results

CASTLE ROCK, Colo., May 14, 2020 (GLOBE NEWSWIRE) — Where Food Comes From, Inc. (WFCF) (OTCQB: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced financial results for its first quarter ended March 31, 2020.“The first quarter is historically our slowest quarter of the year – and Q1 this year was additionally impacted by the devastating effects of Covid-19 on the food supply chain.  As a result, total first quarter revenue declined approximately 1% year over year to $3.9 million from $4.0 million and net loss increased $98,000 to $241,000 from $143,000,” said John Saunders, Chairman and CEO.  “We experienced reduced verification activity due to our customers’ no visitor policies as they strive to keep their facilities open while dealing with workforce...

Continue reading

Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs, including topline data from the Phase 1 clinical trial of KER-050,  at the 25th Annual Congress of the European Hematology Association (“EHA”), to be held as a virtual event from June 11-14, 2020.“We are pleased to be given the opportunity to present at this year’s virtual Congress,” said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros. “We look forward to sharing these exciting data from our two lead...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.